Dana-Farber Cancer Institute

Articles

New Study Unveils Potential Therapeutic Pathways for Aggressive Pediatric Brain Tumor

May 27th 2025

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

Dana-Farber Launches the Ning Zhao & Ge Li Simulation Center to Develop and Train the Next Generation of Oncology Nurses

May 5th 2025

Dana-Farber Cancer Institute opened the Ning Zhao & Ge Li Simulation Center, which is devoted exclusively to ambulatory oncology care.

Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025

April 28th 2025

Dana-Farber Cancer Institute highlights research being presented at the 2025 AACR Annual Meeting.

Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study

April 23rd 2025

Investigators found that the cancer-controlling effects of immune checkpoint inhibitors continue even after treatment is stopped due to immune-related adverse events in patients with advanced NSCLC.

Dana-Farber Researchers Receive AACR 2025 Scientific Achievement Awards

April 16th 2025

Three researchers from Dana-Farber Cancer Institute have been selected by the American Association for Cancer Research (AACR) as recipients of 2025 Scientific Achievement Awards.

Vish Viswanath, PhD, of Dana-Farber Cancer Institute, Elected as Fellow of the American Association for the Advancement of Science

April 14th 2025

K. “Vish” Viswanath, PhD, of Dana-Farber Cancer Center, has been named Fellow of the American Association for the Advancement of Science.

Novel Genomic Screening Tool Enables Precision Reverse-Engineering of Genetic Programming in Cells

April 7th 2025

A study showed transcription factor networks disproportionately enrich for heritability of blood cell phenotypes.

New Patient-Partnered Research Project for Translocation Renal Cell Carcinoma Launches

March 17th 2025

Count Me In, a patient-partnered research initiative led by Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, is launching a project focused on translocation renal cell carcinoma.

Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber

February 21st 2025

Kimberly Stegmaier, MD, was recently named Chair of Pediatric Oncology at Dana-Farber Cancer Institute.

Cancer Vaccine Shows Promise for Patients With Stage III and IV Kidney Cancer

February 10th 2025

Patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma generated successful responses after a personalized cancer vaccine.

AI Model Learns Generalized 'Language' of Regulatory Genomics, Predicts Cellular Stories

February 5th 2025

The model, called EpiBERT, was inspired by BERT, a deep learning model designed to understand and generate human-like language.

Blood Test Could Guide Use of Anti-Inflammatory Drug Celecoxib to Reduce Risk of Colon Cancer Recurrence

January 28th 2025

Patients with evidence of residual cancer in their blood after surgery, may benefit from adding of celecoxib to post surgery treatment.

PET Probe Images Inflammation With High Sensitivity and Selectivity

January 24th 2025

Researchers at Dana-Farber Cancer Institute have developed a breakthrough method to detect inflammation in the body using positron emission tomography (PET) imaging.

Dana-Farber Brigham Cancer Center Recognized for Exceptional Outcomes in Adult Donor Stem Cell Transplants for Fifth Consecutive Year

January 22nd 2025

Stem cell transplant programs at the Dana-Farber Brigham Cancer Center received outstanding reviews from the CIBMTR.

Dana-Farber and Gustave Roussy Announce 2025 Transatlantic Exchange Scientific Program to Focus on Radioligand Therapy

January 16th 2025

Dana-Farber Cancer Institute and Gustave Roussy have announced that the topic of the Fourth Transatlantic Exchange in Oncology Conference will be “Radiopharmaceutical Therapy Meets Oncology.”

Dana-Farber Launches Center for RAS Therapeutics to Target the RAS Oncogene in Cancer

January 8th 2025

Dana-Farber Cancer Institute will launch the Center for RAS Therapeutics to advance scientific investigation and clinical care for RAS-driven cancers.

Dana-Farber Researchers to Present Findings at 2024 San Antonio Breast Cancer Symposium

December 11th 2024

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 47th annual San Antonio Breast Cancer Symposium

Predictive Tool for Melanoma Could Guide Immunotherapy Choices

December 3rd 2024

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.

Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers for 2024

November 21st 2024

Dana-Farber Cancer Institute announced that 42 of its researchers have been named to the Highly Cited Researchers list of 2024.

First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber

November 18th 2024

Investigators are opening a trial to evaluate a novel type of immune cellular therapy in patients with recurrent, platinum-resistant ovarian cancer.